Treatment of New Onset Atrial Fibrillation

Initial Assessment and Treatment Approach

The American College of Cardiology and European Heart Society recommend rate control with chronic anticoagulation as the first-line strategy for most patients with newly detected atrial fibrillation 1, 2
The European Heart Society recommends urgent direct-current cardioversion for patients with hemodynamic instability as the immediate intervention 2, 4
Anticoagulation decisions should be based on stroke risk assessment using validated tools like CHA₂DS₂-VASc score, with anticoagulation recommended for scores ≥2, as suggested by the European Heart Society 2, 3

For patients with left ventricular ejection fraction (LVEF) >40%, the American College of Cardiology recommends beta-blockers, diltiazem, verapamil, or digoxin as first-line medications for rate control 1, 2
Beta-blockers and non-dihydropyridine calcium channel blockers are effective for rate control both at rest and during exercise, according to the American College of Cardiology and European Heart Society 1, 3
A lenient heart rate target of <110 bpm at rest is an appropriate initial goal, as recommended by the European Heart Society 5, 6

Rhythm control should be considered in patients with severe symptoms despite adequate rate control, as suggested by the American College of Cardiology and European Heart Society 1, 3
Electrical cardioversion is the first choice for hemodynamically unstable patients, according to the European Heart Society 2
Pharmacological cardioversion options include flecainide or propafenone for structurally normal hearts, and amiodarone for patients with structural heart disease, as recommended by the European Heart Society 5, 6

The European Heart Society recommends direct oral anticoagulants (DOACs) in preference to vitamin K antagonists for eligible patients 2
For scheduled cardioversion, therapeutic anticoagulation for at least 3 weeks before the procedure is recommended by the European Heart Society 2
Anticoagulation should continue for at least 4 weeks after cardioversion and long-term in patients with thromboembolic risk factors, as suggested by the European Heart Society 2

Underdosing DOACs can be harmful, and reduced doses should only be used when patients meet specific criteria, according to the European Heart Society 2
Using rhythm control without appropriate anticoagulation increases stroke risk, as warned by the American College of Cardiology and European Heart Society 1, 2
Relying on digoxin alone for rate control in physically active patients is not effective, as it only controls heart rate at rest, according to the American College of Cardiology and European Heart Society 1, 3

For patients with atrial fibrillation and Wolff-Parkinson-White syndrome, prompt direct-current cardioversion is recommended if hemodynamically compromised, as suggested by the American Heart Association 4
For patients with pre-excited atrial fibrillation, adenosine, digoxin, and non-dihydropyridine calcium channel blockers should be avoided as they can accelerate ventricular rate, according to the American Heart Association 4
For patients with hypertrophic cardiomyopathy, anticoagulation is indicated regardless of CHA₂DS₂-VASc score, as recommended by the American Heart Association 4